A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 787-794

  Perreault, Sylvie ^a   Hamilton, Vivian H ^a,b   Lavoie, Frédéric ^a   Grover, Steven ^a,b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cost effectiveness; Fibrates; HMG CoA reductase inhibitors; Primary hyperlipidemia

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPIDEMIAS; MALE; PROCETOFEN;

EID: 0030965610     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053037     Document Type: Article

References (40)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I: Reduction in incidence of coronary heart disease. JAMA 1984;251: 351-364.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
3. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986;256:2823-2828.
4. Tyroler HA. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987;76:515-522.
5. Frick MH, Elo O, Olli E, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
6. Grover SA, Coupal L, Fakhry R, Suissa S. Screening for hypercholesterolemia among Canadians: How much will it cost? Can Med Assoc J 1991;144:161-168.
7. Garber AM, Sox HC Jr, Littenberg B. Screening asymptomatic adults for cardiac risk factors: The serum cholesterol level. Ann Intern Med 1989;110:622-639.
8. Tood PA, Goa KL. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990;40:583-607.
9. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994;78:225-245.
10. Betteridge DJ, Durrington PN, Fairhurst GJ, et al. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994;96:45S-54S.
11. Greten H, Beil FU, Schneider J, et al. Treatment of primary hypercholesterolemia: Fluvastatin versus bezafibrate. Am J Med 1994;96:55S-63S.
12. Crepaldi G, Baggio G, Area M, et al. Pravastatin vs. gemfibrozil in the treatment of primary hypercholesterolemia. The Italian multicenter pravastatin study I. Arch Intern Med 1990;151:146-152.
13. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994;154:441-449.
14. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20.
15. Tikkanen MJ, Helve E, Jaattela A, et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish multicenter study. Am J Cardiol 1988;62:35J-43J.
16. Tikkanen MJ, Bocanegra TS, Walker JF, Cook T. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. Am J Med 1989;87:47S-53S.
17. Ziegler O, Drouin P. Simvastatin-Fenofibrate Study Group. Safety, tolerability, and efficacy of simvastatin and fenofibrate - A multicenter study. Cardiology 1990;77:50-57.
18. Miele NF, Page D. Controversial costs of cocaine. JAMA 1992;267:507-508.
19. Canadian Heart Health Surveys: A profile of cardiovascular risk. Can Med Assoc J 1992;(suppl):28-36.
20. Ontario Ministry of Health. Schedule of Benefits: Physician Services, 1989. Toronto: Ontario Ministry of Health, 1989.
21. Régie d'Assurance Maladie du Québec. Manuel des Médecins Omnipraticiens RAMQ. Québec, Québec: Régie de l'Assurance-Maladie du Québec, 1989.
22. Régie d'Assurance Maladie du Québec. Manuel des Médecins Specialistes RAMQ. Québec, Québec: Régie de l'Assurance-Maladie du Québec, 1989.
23. Grover SA, Abrahamowicz M, Joseph L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA 1992;267:816-822.
24. Abbott RD, McGee D. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, MD: U.S. Government Printing Office, 1987, section 37. U.S. Department of Health, Education, and Welfare Publication no. NIH 87-2284.
25. Statistics Canada, Health Division. Life Tables, Canada, and Provinces, 1985-1987. Ottawa, Ontario: Vital Statistics and Diseases Registries Section, 1989. Formely catalogue no. 84-532.
26. Kannel WB, Wolf PA, Garrison RJ. Survival following initial cardiovascular events: 30 years follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, MD: National Heart, Lung, and Blood Institute, 1988, section 35. National Heart, Lung and Blood Institute publication no. NIH 88-2969.
27. Grover SA, Coupal L. Risk benefit assessment of drug treatment to prevent heart disease. Drug Safety 1994;10: 301-309.
28. Grover SA, Coupal L, Hu X. Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? JAMA 1995;274:801-806.
29. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651.
30. Hamilton HV, Racicot FE, Zowall H, Coupal L, Grover S. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-1038.
31. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Trials Group. N Engl J Med 1995;333:1301-1307.
33. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992;85:37-45.
34. Frick MH, Heinonen OP, Huttunen JK, et al. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study Frame Population. Ann Med 1993;25:41-45.
35. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: The importance of considering initial level of risk. Br Med J 1993;306:1367-1373.
36. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit, a new look at old data. Circulation 1995;91:2274-2282.
37. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996;124:518-531.
38. Newman TB, Hulley SB. Carcinogenicity of lipid lowering drug. JAMA 1996;275:55-60.
39. Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: A billion dollar question. Ann Intern Med 1980;92:243.
40. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987;25:25-34.